SCHEMBL8937649

SCHEMBL8937649

CCOc1ccc(/C(=C\C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cc(Cl)ccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
ALDH1A1 P00352 6/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MAPT P10636 2/20 0.48
CYP1A2 P05177 1/20 0.45
HSD17B10 Q99714 2/20 0.45
TP53 P04637 1/20 0.45
F10 P00742 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937653 1.00 LMNA (0.55) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937526 0.92 ALDH1A1 (0.62) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937523 0.92 ALDH1A1 (0.62) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937599 0.92 ALDH1A1 (0.62) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937608 0.87 ALDH1A1 (0.55) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937461 0.87 ALDH1A1 (0.55) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937466 0.87 ALDH1A1 (0.55) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937337 0.84 ALDH1A1 (0.62) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937332 0.84 ALDH1A1 (0.62) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9
SCHEMBL8937359 0.84 ALDH1A1 (0.52) LMNAALDH1A1L3MBTL1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed